Routine Metagenomics Service for ICU Patients with Respiratory Infection

Rationale: Respiratory metagenomics (RMg) needs evaluation in a pilot service setting to determine utility and inform implementation into routine clinical practice. Objectives: Feasibility, performance, and clinical impacts on antimicrobial prescribing and infection control were recorded during a pilot RMg service. Methods: RMg was performed on 128 samples from 87 patients with suspected lower respiratory tract infection (LRTI) on two general and one specialist respiratory ICUs at Guy's and St Thomas' NHS Foundation Trust, London. Measurements and Main Results: During the first 15 weeks, RMg provided same-day results for 110 samples (86%), with a median turnaround time of 6.7 hours (interquartile range = 6.1-7.5 h). RMg was 93% sensitive and 81% specific for clinically relevant pathogens compared with routine testing. Forty-eight percent of RMg results informed antimicrobial prescribing changes (22% escalation; 26% deescalation) with escalation based on speciation in 20 out of 24 cases and detection of acquired-resistance genes in 4 out of 24 cases. Fastidious or unexpected organisms were reported in 21 samples, including anaerobes (n = 12), Mycobacterium tuberculosis, Tropheryma whipplei, cytomegalovirus, and Legionella pneumophila ST1326, which was subsequently isolated from the bedside water outlet. Application to consecutive severe community-acquired LRTI cases identified Staphylococcus aureus (two with SCCmec and three with luk F/S virulence determinants), Streptococcus pyogenes (emm1-M1uk clone), S. dysgalactiae subspecies equisimilis (STG62647A), and Aspergillus fumigatus with multiple treatments and public health impacts. Conclusions: This pilot study illustrates the potential of RMg testing to provide benefits for antimicrobial treatment, infection control, and public health when provided in a real-world critical care setting. Multicenter studies are now required to inform future translation into routine service.

Errataetall:

CommentIn: Am J Respir Crit Care Med. 2024 Jan 15;209(2):124-126. - PMID 38029295

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:209

Enthalten in:

American journal of respiratory and critical care medicine - 209(2024), 2 vom: 15. Jan., Seite 164-174

Sprache:

Englisch

Beteiligte Personen:

Charalampous, Themoula [VerfasserIn]
Alcolea-Medina, Adela [VerfasserIn]
Snell, Luke B [VerfasserIn]
Alder, Christopher [VerfasserIn]
Tan, Mark [VerfasserIn]
Williams, Tom G S [VerfasserIn]
Al-Yaakoubi, Noor [VerfasserIn]
Humayun, Gul [VerfasserIn]
Meadows, Christopher I S [VerfasserIn]
Wyncoll, Duncan L A [VerfasserIn]
Paul, Richard [VerfasserIn]
Hemsley, Carolyn J [VerfasserIn]
Jeyaratnam, Dakshika [VerfasserIn]
Newsholme, William [VerfasserIn]
Goldenberg, Simon [VerfasserIn]
Patel, Amita [VerfasserIn]
Tucker, Fearghal [VerfasserIn]
Nebbia, Gaia [VerfasserIn]
Wilks, Mark [VerfasserIn]
Chand, Meera [VerfasserIn]
Cliff, Penelope R [VerfasserIn]
Batra, Rahul [VerfasserIn]
O'Grady, Justin [VerfasserIn]
Barrett, Nicholas A [VerfasserIn]
Edgeworth, Jonathan D [VerfasserIn]

Links:

Volltext

Themen:

Anti-Infective Agents
Journal Article

Anmerkungen:

Date Completed 15.01.2024

Date Revised 26.01.2024

published: Print

CommentIn: Am J Respir Crit Care Med. 2024 Jan 15;209(2):124-126. - PMID 38029295

Citation Status MEDLINE

doi:

10.1164/rccm.202305-0901OC

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM364299134